NGM Biopharmaceuticals Inc (NASDAQ:NGM)
| 18.08 Delayed Data As of Dec 03 |  -0.64 / -3.42%Today’s Change | 14.90 Today|||52-Week Range 32.12 | -40.32% Year-to-Date |
Latest NGM News | Press Releases
No recent news for NGM Biopharmaceuticals Inc.
Today’s Trading
| Previous close | 18.72 |
| Today’s open | 18.54 |
| Day’s range | 17.70 - 18.64 |
| Volume | 14,393 |
| Average volume (3 months) | 338,471 |
| Market cap | $1.4B |
Data as of 3:59pm ET, 12/03/2021
Growth & Valuation
| Earnings growth (last year) | -75.92% |
| Earnings growth (this year) | -4.11% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -15.62% |
| P/E ratio | NM |
| Price/Sales | 23.74 |
| Price/Book | 4.67 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| IMGNImmunoGen Inc | -0.52 | -7.26% |
| MYOVMyovant Sciences Ltd | -0.81 | -5.24% |
| CHRSCoherus BioSciences ... | -0.29 | -1.61% |
| REPLReplimune Group Inc | -1.28 | -4.42% |
Data as of 5:30pm ET, 12/03/2021
Financials
| Next reporting date | March 22, 2022 |
| EPS forecast (this quarter) | -$0.35 |
| Annual revenue (last year) | $87.4M |
| Annual profit (last year) | -$102.5M |
| Net profit margin | -117.30% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters South San Francisco, California |
Forecasts
